Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQuadrise Regulatory News (QED)

Share Price Information for Quadrise (QED)

Share Price is delayed by 15 minutes
Get Live Data
2.10    0.21 (11.11%)
Bid:
1.805
Ask:
2.09
Spread: 0.285 (15.789%)
Market Cap: £42.13m
QED Live PriceLast checked at - London Stock Exchange

Intraday Quadrise Share Chart

Disposal

11 Sep 2009 07:00

RNS Number : 8892Y
Quintain Estates & Development PLC
11 September 2009
 



11 September 2009 

Quintain Estates & Development plc

("Quintain" / "Company" / "Group")

QUINTAIN REPATRIATES A FURTHER £31.3 MILLION OF CASH

Quintain announces the sale of units in The Quercus Healthcare Property Partnership ("Quercus" / the "Fund"for a total cash consideration of £31.3 million. The units have been sold to a number of UK institutional pension funds through the anonymous matched bargain dealing facility provided by Aviva Investors, Quintain's partner in the Fund.

This transaction was undertaken as part of Quintain's strategy to repatriate cash and reduce gearing, thereby enhancing the Company's financial flexibility. The proceeds of the disposal bring the total amount of cash repatriated since 1 April 2009 to over £42 million, representing 85% of the £50 million Quintain had targeted to raise in the year to 31 March 2010. The total cash repatriated by the Group since 1 April 2008 is now £140 million. 

Quercus is the largest fund within Quintain Fund Management. As at 30 June 2009, it had £759.9 million in funds under management and owned 264 assets, comprising nursing and residential care homes for the elderly, specialist care homes for those with long term disabilities, private hospitals, and care villages. The units were sold at a 12% discount to the Fund's reported NAV at July and a discount to Quintain's March valuation of £10.8mrepresenting a loss against book cost of £1.8 million. In the last twelve months, the units delivered £2.5 million of income to the Group

As a result of this disposalQuintain's total holding in Quercus is reduced from 25.4% to 16% and the number of investors in the Fund has increased to 50.

Rebecca Worthington, Finance Director of Quintain, commented: 

"This disposal represents another important milestone in our cash repatriation programme, taking the total raised to 85% of the £50 million we intend to repatriate by 31 March 2010 and thereby further enhancing Quintain's financial flexibility and control over interest costs."

For further information, please contact:

Quintain Estates & Development plc

Rebecca Worthington / Tonianne Dwyer / Cressida Curtis

Tel: +44 (0) 20 7495 8968

Financial Dynamics

Stephanie Highett / Dido Laurimore / Laurence Jones 

Tel: +44 (0) 20 7831 3113

Notes to Editors

Quintain Fund Management ("QFM") uses specialist property expertise to create value in its funds operating in three sectors with high barriers to entry: healthcare (Quercus), student accommodation (iQ) and science parks (Quantum). Each fund is underpinned by strong demographics such as an ageing population and increasing numbers of people entering higher education. The Funds interact with Quintain's other businesses, taking space on our major schemes, using the asset management skills within the Investment Portfolio and generating income that is used across the Group.

As at 31 March 2009, QFM's funds under management were £980 million.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DISILFSRAIIILIA
Date   Source Headline
1st Aug 20247:00 amRNSValkor Project Update
10th Jul 20247:00 amRNSMarine Project Update
26th Jun 20247:00 amRNSExtended agreement with BTG Bioliquids for bioMSAR
29th May 20247:00 amRNSRepresentation Agreement Addendum & Warrants Grant
28th May 20247:00 amRNSOCP Commercial Framework Agreement
2nd May 20247:00 amRNSQuadrise-Vertoro JDA to sea-trial bioMSAR Zero
29th Apr 20247:00 amRNSMarine Project Update
19th Apr 20247:00 amRNSValkor Project Update
12th Apr 20244:58 pmRNSResults of Open Offer
22nd Mar 20243:10 pmRNSExtension of Open Offer Closing Date
20th Mar 20241:01 pmRNSInvestor Presentation
19th Mar 20247:00 amRNSPlacing Results, Open Offer & Posting of Circular
18th Mar 20244:55 pmRNSProposed Placing, Subscription and Open Offer
18th Mar 20244:53 pmRNSInterim Results
15th Feb 20247:00 amRNSAgreement with Euthenia & BTG Bioliquids
6th Feb 20247:00 amRNSMarine Project Update
6th Dec 20237:00 amRNSUpdate re bioMSARâ„¢ and bioMSARâ„¢ Zero Development
27th Nov 20235:46 pmRNSResult of AGM
27th Nov 20237:00 amRNSAGM Statement
22nd Nov 20237:00 amRNSMorocco Project Update
9th Nov 20237:00 amRNSPublication of 2023 Sustainability Report
31st Oct 202312:45 pmRNSMorocco Project Update
27th Oct 20234:20 pmRNSPosting of Annual Report & Notice of AGM
24th Oct 20239:33 amRNSChange of Nominated Adviser
2nd Oct 20237:30 amRNSDirectorate Change
2nd Oct 20237:00 amRNSFinal Results and Notice of AGM
12th Sep 20237:00 amRNSMorocco Project Update
29th Aug 20237:00 amRNSValkor Project Update
24th Aug 202312:29 pmRNSValkor Update
18th Aug 20233:46 pmRNSMorocco Update
4th Aug 20237:00 amRNSIssue of Share Options and Director/PDMR Dealing
1st Aug 20234:15 pmRNSDirector/PDMR Shareholding
28th Jul 20234:25 pmRNSDirector/PDMR Shareholding
25th Jul 20233:34 pmRNSResults of Open Offer
7th Jul 202312:00 pmRNSInvestor Presentation
7th Jul 202310:38 amRNSPlacing Results, Open Offer & Posting of Circular
7th Jul 20237:00 amRNSProposed Placing and Open Offer
22nd Jun 20237:00 amRNSMorocco Update
12th Jun 20237:00 amRNSValkor Site License & Supply Agreement
8th Jun 20237:00 amRNSJoint Development Agreement with BTG Bioliquids
26th May 20237:00 amRNSVertoro Joint Development Agreement Update
22nd May 20237:00 amRNSMorocco Update
16th May 20234:29 pmRNSReplacement: Business Update
16th May 20237:00 amRNSBusiness Update
25th Apr 20237:00 amRNSAppointment of Joint Broker
29th Mar 20237:00 amRNSInterim Results
28th Mar 20237:00 amRNSChange of Company Name
22nd Oct 20155:26 pmRNSDelisting of Quintain ordinary shares
15th Oct 20154:30 pmRNSHolding(s) in Company
15th Oct 20154:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.